Clinical and molecular evaluation of therapy with the use of cyclosporine A in patients with psoriasis vulgaris.
Anna Michalska-BańkowskaDominika Wcisło-DziadeckaBeniamin GrabarekUrszula MazurekLigia Brzezińska-WcisłoPiotr MichalskiPublished in: International journal of dermatology (2018)
TGFb1 may be claimed as the supplementary molecular marker to evaluate the efficacy of CsA therapy. It seems that systemic diseases have an effect on the efficacy of the applied pharmacotherapy and the course of psoriasis.